Activation of protease‐activated receptor 2 is associated with blood pressure regulation and proteinuria reduction in metabolic syndrome. (21st November 2020)

• Record Type: Journal Article
• Authors: Maruyama‐Fumoto, Kana; McGuire, John J.; Fairlie, David P.; Shinozuka, Kazumasa; Kagota, Satomi
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 48:Number 2(2021)
• Page Start: 211
• Page End: 220
• Publication Date: 2020-11-21
• Subjects: metabolic syndrome -- protease‐activated receptor‐2 -- proteinuria -- renal artery -- vasorelaxation; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.13431
• Languages: English
• ISSNs: 0305-1870

Abstract

Abstract: Metabolic syndrome (MetS) increases the risk of kidney disease. In SHRSP.Z‐ Lepr fa /IzmDmcr (SHRSP.ZF) rats with MetS, protease‐activated receptor 2 (PAR2)‐mediated vasorelaxation is preserved in the aorta at 20 weeks of age (weeks) via enhancement of nitric oxide production but impaired at 30 weeks by oxidative stress. However, impairment of PAR2‐mediated vasorelaxation of renal arteries and its possible implications for kidney disease are unclear. We used organ baths to assess PAR2‐mediated vasorelaxation of isolated renal arteries, colorimetric methods to measure urinary protein levels as an index of renal function, and western blot to determine expression of PAR2 and nephrin proteins in the kidneys of SHRSP.ZF rats at 10, 20, and 30 weeks. We assessed renal arteries and kidney function for effects of orally administered GB88, a pathway‐dependent PAR2 antagonist, from 10 to 18 weeks, and azilsartan, an angiotensin II type 1 receptor blocker, from 13 to 23 weeks. PAR2‐mediated vasorelaxation was slightly lower at 20 weeks and attenuated significantly at 30 weeks compared with those at 10 weeks. Urinary protein levels were increased at 20 and 30 weeks. Decreased protein expression of PAR2 and nephrin in the kidney were observed at 30 weeks. Administration of GB88 increased blood pressure (BP) and proteinuria. Azilsartan reduced the high BP and the impaired PAR2‐mediated vasorelaxation, but did not restore the increase in urinary protein levels and decreased PAR2 and nephrin protein expression in the kidney. PAR2 activation in the kidney may be associated with maintenance of BP and urinary protein excretion in MetS. Abstract : PAR2 inhibition in vitro exacerbates high blood pressure and kidney dysfunction in aging rats with metabolic syndrome (MetS)